Skip to main content

Table 4 The key reported clinical trials of PD-1/PD-L inhibitors in patients with pancreatic cancer

From: PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

Tumor type Target Drug Phase and identification Sample size Clinical end point TRAEs Reference
PC PD-L1 Durvalumab Phase I/II
29 ORR 7%; 12-week DCR 21% Any grade (multiple cancer types) 33%, including fatigue, nausea, rash, vomiting, and pyrexia; grade ≥3 (multiple cancer types) 7% ASCO 2014 [61]
PC PD-L1 MDX1105-01 Phase I 14 ORR 0% Grades 3–4 (multiple cancer types) 9% The New England Journal of Medicine [60]